Literature DB >> 8781157

Perivascular inflammatory reaction after percutaneous placement of covered stents.

J Link1, S Müller-Hülsbeck, J Brossmann, J C Steffens, M Heller.   

Abstract

A 52-year-old woman with an extensive superficial femoral artery occlusion was treated with percutaneous transluminal angioplasty. Because of extensive dissections, two covered stents were placed percutaneously. The intervention was successful with respect to vessel patency, but local pain and fever developed 5 hr after the intervention. Swelling of the thigh occurred, but deep venous thrombosis was excluded. MRI revealed pronounced soft-tissue edema in the adductor canal that persisted for 4 weeks. The fever responded to antiinflammatory medication, but the pain remained for 4 weeks. The vessel was patent at the last follow-up, 8 weeks after graft placement. Soft-tissue edema after percutaneous placement of covered stents has been reported previously. The cause of the inflammatory reaction is unclear.

Entities:  

Mesh:

Year:  1996        PMID: 8781157     DOI: 10.1007/bf02570188

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  3 in total

1.  Initial experience with the Cragg Endopro System 1 for intraluminal treatment of peripheral vascular disease.

Authors:  M Henry; M Amor; G Ethevenot; I Henry; W Abdelwahab; E Leborgne; M Allaoui
Journal:  J Endovasc Surg       Date:  1994-09

2.  Percutaneous femoropopliteal graft placement.

Authors:  A H Cragg; M D Dake
Journal:  Radiology       Date:  1993-06       Impact factor: 11.105

3.  Nitinol intravascular stent: results of preclinical evaluation.

Authors:  A H Cragg; S C De Jong; W H Barnhart; S K Landas; T P Smith
Journal:  Radiology       Date:  1993-12       Impact factor: 11.105

  3 in total
  1 in total

1.  Viabahn for femoropopliteal in-stent restenosis.

Authors:  Owayed Al Shammeri; Fahad Bitar; Jaime Ghitelman; Peter A Soukas
Journal:  Ann Saudi Med       Date:  2012 Nov-Dec       Impact factor: 1.526

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.